Market Research Future

Attention Deficit Hyperactivity Disorder Therapeutics Market 2023 by Competitors Analysis, Key Venders, Research, Trends and Segments

The Industry report for “Global ADHD Therapeutics market” by Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the industry performance.


Pune, India -- (SBWIRE) -- 12/12/2018 -- ADHD Therapeutics Market - Scenario

Attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder with a group of behavioral symptoms that include hyperactivity, inattentiveness and impulsiveness. The symptoms of ADHD begin in childhood and can continue through adolescence and adulthood.

As per the report published by Market Research Future (MRFR), the global ADHD therapeutics market is registered to grow steadily till the end of 2024.


ADHD Therapeutics Market - Key Players

Concordia International Corp.

Eli Lilly and Company

Highland Therapeutics Inc.

Janssen Global Services LLC

NEOS Therapeutics Inc.

Novartis AG

Noven Pharmaceuticals Inc.

Pfizer Inc.


Teva Pharmaceutical

ADHD Therapeutics Market - Segmentation

The global ADHD therapeutics market has been segmented on the basis of drug type and distribution channel. Based on drug type, the ADHD therapeutics market is segmented into stimulants and non-stimulants.

The stimulants segment is sub-segmented into amphetamine, methylphenidate, dextroamphetamine, lisdexamfetamine and others. The non-stimulants segment is sub-segmented into atomoxetine, bupropion, guanfacine and clonidine

Based on distribution channel, the ADHD therapeutics market is segmented into hospitals, clinics, pharmacies, research laboratories and others.

ADHD Therapeutics Market - Regional Analysis

Geographically, the Global ADHD Therapeutics Market is segmented into four major regions such as North America, Europe, Asia Pacific and the Middle East and Africa. The ADHD therapeutics market in the North America region accounts for the dominant share in the global ADHD therapeutics market owing to the increasing prevalence of ADHD in the children and high healthcare expenditure by the population in this region.

The ADHD therapeutics market in the Europe region is projecting significant growth owing to the increased research and development for the introduction of more effective drugs in this region. The Asia Pacific region is anticipated to grow at a notable pace in the coming years due to increased awareness regarding ADHD and its available treatments.

Whereas, the Middle East and Africa region is projecting steady growth in the global ADHD market owing to the low awareness and poor primary health care in the underdeveloped areas of this region.

ADHD Therapeutics Market - Drivers and Restraints

The symptoms of ADHD such as lack of attention, hyperactivity and impulsivity hamper proper functioning and development of an individual. Increasing awareness regarding neurodevelopmental disorders and easy availability of diagnostic guidelines over the internet is projected to boost the growth of the global ADHD therapeutics market.

Changing lifestyles and value systems along with the factors like genetic inheritance and premature birth are resulting to the rise in prevalence of ADHD among children in the age group of 4-17 years, which in turn is propelling the growth of the global ADHD therapeutics market.

Increasing availability of online platforms for therapists that assure anonymity of the patient is inclining more individuals towards undergoing therapeutic treatment for ADHD, which in turn is fueling the expansion of the global ADHD therapeutics market

However, underdiagnosis of ADHD due to the existence of comorbid conditions in children, lack of awareness and low availability of non-stimulant drugs to treat ADHD in various regions are likely to hamper the expansion of the global ADHD therapeutics market during the forecast period.


ADHD Therapeutics Market - Industry Updates

In August 2018, Ironshore Pharmaceuticals & Development, Inc., a subsidiary of Highland Therapeutics Inc., has received FDA approval for the New Drug Application for Jornay PM (methylphenidate) which was formerly known as HLD200 which is used for the treatment of ADHD in patients of the age six and older

In August 2018, FDA has issued a Complete Response Letter (CRL) to Sunovion Pharmaceutical asking for further clinical data to evaluate the efficacy of dasotraline, the ADHD drug.

Major Points form TOC for ADHD Therapeutics Market Research Report – Forecast to 2024

Chapter 1. Report Prologue

Chapter 2. Market Introduction

Chapter 3. Research Methodology

Chapter 4. Market Dynamics

Chapter 5. Market Factor Analysis

Chapter 6. Global ADHD Therapeutics Market, By Type

Chapter 7. Global ADHD Therapeutics Market, By Treatment

Chapter 8 Global ADHD Therapeutics Market, By End User

Chapter 9. Global ADHD Therapeutics Market, By Region

Chapter 10 Company Landscape

Chapter 11 Company Profiles

Chapter 12 MRFR Conclusion

Chapter 13 Appendix

About Market Research Future
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.